Gilead Sciences Q1 revenue rises 4% to $7.0 billion; 2026 EPS guidance cut to a loss
Gilead reported first-quarter 2026 total revenue of $7.0 billion, up 4% from a year earlier, and GAAP diluted EPS of $1.61 versus $1.04. The company cut its full-year 2026 GAAP diluted EPS guidance to a loss of $(3.25) to $(2.85) from $6.75 to $7.15, citing anticipated acquired IPR&D charges of $11.5 billion and financing costs tied to the Arcellx, Ouro and Tubulis acquisitions, while raising its product sales guidance.
Key points
- Q1 2026 total revenues rose 4% to $7.0 billion; GAAP diluted EPS was $1.61 versus $1.04 and non-GAAP diluted EPS was $2.03 versus $1.81.
- Full-year 2026 GAAP diluted EPS guidance is $(3.25) to $(2.85), down from $6.75 to $7.15; non-GAAP guidance is $(1.05) to $(0.65), down from $8.45 to $8.85.
- Full-year 2026 product sales guidance was raised to $30.0 billion to $30.4 billion from $29.6 billion to $30.0 billion.
- Cash and marketable debt securities fell to $8.6 billion at March 31, 2026, from $10.6 billion at December 31, 2025; the Board declared a $0.82 quarterly dividend payable June 29, 2026.
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.